TIDMORPH
RNS Number : 2693W
Open Orphan PLC
21 December 2021
21 December 2021
Open Orphan plc
("Open Orphan" or the "Company")
GBP5m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in vaccine
and antiviral testing using human challenge clinical trials ,
announces that hVIVO , a subsidiary of Open Orphan plc, has signed
a GBP5m influenza human challenge study contract with a biotech
company developing an antiviral drug for protection against
respiratory viral infections.
The study, which is expected to commence in H2 2022, will test
and assess the efficacy of a single dosing regimen of the client's
antiviral drug, with healthy adult volunteers, using the hVIVO
Influenza human challenge study model. Conducted at hVIVO's
state-of-the-art facilities in London, Open Orphan expects the
majority of revenues to be recognised in 2022.
Respiratory tract infections are infections of parts of the body
involved in breathing, such as the sinuses, throat, airways or
lungs and are often caused by viruses such as influenza. Seasonal
influenza causes significant morbidity and mortality each year and
a pandemic influenza continues to pose a worldwide threat.
Influenza is a serious global health threat with an estimated 1
billion cases per year, 3-5 million severe cases and 290,000 -
650,000 deaths per year. Healthy volunteer human challenge studies
of wild-type influenza play a major role in the development of
vaccines and therapeutics against influenza.
hVIVO has been studying influenza for over 20 years and
conducting influenza human challenge studies with its flu disease
models for more than 15 years. hVIVO has conducted numerous flu
challenge studies for a range of industry, governmental and
academic clients, making its models the most well-used commercial
flu disease models available on the market. hVIVO also has
expertise in safely conducting challenge studies across a range of
respiratory viruses, including various strains of Influenza,
Respiratory Syncytial Virus (RSV) and human Rhinovirus HRV (common
cold virus), malaria, and asthma. In October 2020, this expanded to
include the SARS-CoV-2 virus.
Cathal Friel, Executive Chairman of Open Orphan, said : "We are
delighted to be working with this biotech client to assess the
efficacy of their antiviral product which has the potential to be
an important treatment against respiratory viral infections, using
the hVIVO Influenza human challenge study model .
"We have now signed contracts for 95% of our 2022 forecasted
revenues. This is the fourth Influenza human challenge study that
we have signed in 2021 and coupled with the contract wins that we
have seen in other disease areas, this further underlines the
growing interest in respiratory and infectious diseases within the
pharmaceutical and biotechnology industries, which we expect to
continue over the coming years.
"Additionally, the continued damaging effects of the COVID-19
pandemic have underlined the need for increased pandemic
preparedness in relation to other potential pandemic infectious
diseases, such as influenza. Our expertise in testing vaccines and
antivirals against our portfolio of infectious disease human
challenge models will be important in ensuring we are prepared for
the next, potentially more dangerous pandemic disease."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 (as implemented into
English law) ("MAR"). With the publication of this announcement via
a Regulatory Information Service, this inside information is now
considered to be in the public domain.
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . By volunteering to take part in one of
our studies in a safe, controlled, clinical environment under
expertly supervised conditions you are playing your part to further
medical research and help increase the understanding of respiratory
illnesses.
Individuals interested in taking part in COVID-19 human
challenge study research can learn more at www.UKCovidChallenge.com
.
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Louisa Waddell
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR +44 (0)20 7933 8780 or openorphan@walbrookpr.com
& IR)
Paul McManus/ Sam Allen/ Louis Ashe-Jepson +44 (0)7980 541 893 / +44
(0) 7502 558 258 / +44 (0)
7747 515393
Notes to Editors
Open Orphan plc
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
pharmaceutical service/contract research company that is a world
leader in testing vaccines and antivirals using human challenge
clinical trials. The Company provides services to Big Pharma,
biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic and its state-of-the-art
24-bedroom QMB clinic with its highly specialised on-site virology
and immunology laboratory. Open Orphan has a leading portfolio of
human challenge study models for infectious and respiratory
diseases and is developing a number of other models. There has been
an explosion in the growth of the infectious disease
pharmaceuticals market, which is estimated to grow to in excess of
$250bn by 2025. The Group is focused on refreshing its existing
challenge models and develop new models, such as Malaria, to
address the dramatic growth potential of the global infectious
disease market.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma and biotech companies.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFLFSAFRLIFIL
(END) Dow Jones Newswires
December 21, 2021 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Hvivo (LSE:HVO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
